دورية أكاديمية
أعرض في EDS

Development and Evaluation of Microencapsulated Oregano Essential Oil as an Alternative Treatment for Candida albicans Infections.

التفاصيل البيبلوغرافية
العنوان: Development and Evaluation of Microencapsulated Oregano Essential Oil as an Alternative Treatment for Candida albicans Infections.
المؤلفون: Fernandes L; Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal., Barco-Tejada A; Departamento de Bioingeniería, Universidad Carlos III de Madrid, 126, 28903 Getafe, Madrid, Spain.; Unidad de Medicina y Cirugía Experimenta, Instituto de Investigación Sanitaria Gregorio Marañón, 28029 Madrid, Spain., Blázquez E; Departamento de Bioingeniería, Universidad Carlos III de Madrid, 126, 28903 Getafe, Madrid, Spain.; Unidad de Medicina y Cirugía Experimenta, Instituto de Investigación Sanitaria Gregorio Marañón, 28029 Madrid, Spain., Araújo D; Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.; National Institute for Agrarian and Veterinary Research, Vairão, 4485-655 Vila do Conde, Portugal.; LABBELS - Associate Laboratory, 4710-057 Braga, Portugal., Ribeiro A; Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.; LABBELS - Associate Laboratory, 4710-057 Braga, Portugal., Silva S; Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.; National Institute for Agrarian and Veterinary Research, Vairão, 4485-655 Vila do Conde, Portugal.; LABBELS - Associate Laboratory, 4710-057 Braga, Portugal., Cussó L; Departamento de Bioingeniería, Universidad Carlos III de Madrid, 126, 28903 Getafe, Madrid, Spain.; Advanced Imaging Unit, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain.; CIBER de Salud Mental, Instituto de Salud Carlos III, 28029 Madrid, Spain., Costa-de-Oliveira S; Division of Microbiology, Department of Pathology, and Center for Health Technology and Services Research - CINTESIS@RISE, Faculty of Medicine, University of Porto, 4200-450 Porto, Portugal., Rodrigues ME; Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.; LABBELS - Associate Laboratory, 4710-057 Braga, Portugal., Henriques M; Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.; LABBELS - Associate Laboratory, 4710-057 Braga, Portugal.
المصدر: ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2024 Aug 07; Vol. 16 (31), pp. 40628-40640. Date of Electronic Publication: 2024 Jul 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101504991 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1944-8252 (Electronic) Linking ISSN: 19448244 NLM ISO Abbreviation: ACS Appl Mater Interfaces Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, D.C. : American Chemical Society
مواضيع طبية MeSH: Candida albicans*/drug effects , Candida albicans*/physiology , Oils, Volatile*/chemistry , Oils, Volatile*/pharmacology , Candidiasis, Vulvovaginal*/drug therapy , Candidiasis, Vulvovaginal*/microbiology , Mice, Inbred BALB C* , Antifungal Agents*/pharmacology , Antifungal Agents*/chemistry , Origanum*/chemistry, Animals ; Female ; Mice ; Biofilms/drug effects ; Microbial Sensitivity Tests ; Humans
مستخلص: Vulvovaginal candidiasis (VVC) is characterized as a very common fungal infection that significantly affects women's health worldwide. Essential oils (EOs) are currently being evaluated as an alternative therapy. The development of efficient techniques such as micro- or nanoencapsulation for protecting and controlling release is essential to overcome the limitations of EO applications. Therefore, the aim of this study was to develop and characterize oregano EO-loaded keratin microparticles (OEO-KMPs) as a potential treatment for VVC. OEO-KMPs were produced using high-intensity ultrasonic cycles and characterized in terms of morphological and physicochemical parameters. In vitro evaluation included assessing the toxicity of the OEO-KMPs and their effect against Candida albicans using microdilution and agar diffusion, while the activity against biofilm was quantified using colony forming units (CFU). The efficacy of the OEO-KMPs in an in vivo VVC mouse model was also studied. Female BALB/c mice were intravaginally infected with C. albicans , 24 h postinfection animals were treated intravaginally with 15 μL of OEO-KMPs and 24 h later vaginal fluid was analyzed for C. albicans and Lactobacillus growth (CFU mL -1 ). The results showed the stability of the OEO-KMPs over time, with high encapsulation efficiency and controlled release. This nanoparticle size facilitated penetration and completely inhibited the planktonic growth of C. albicans . In addition, an in vitro application of 2.5% of the OEO-KMPs eradicated mature C. albicans biofilms while preserving Lactobacillus species. In in vivo , a single intravaginal application of OEO-KMPs induced a reduction in C. albicans growth, while maintaining Lactobacillus species. In conclusion, this therapeutic approach with OEO-KMPs is promising as a potential alternative or complementary therapy for VVC while preserving vaginal microflora.
References: Int J Cosmet Sci. 2018 Aug;40(4):408-419. (PMID: 30047992)
Curr Protoc Neurosci. 2009 Jul;Appendix 4:Appendix 4I. (PMID: 19575469)
Appl Microbiol Biotechnol. 2020 Oct;104(20):8911-8924. (PMID: 32880694)
J Conserv Dent. 2021 Sep-Oct;24(5):457-463. (PMID: 35399768)
J Nanobiotechnology. 2018 Sep 19;16(1):71. (PMID: 30231877)
Pharmaceutics. 2021 Mar 03;13(3):. (PMID: 33802570)
Int J Biol Macromol. 2023 Apr 30;235:123897. (PMID: 36870638)
J Med Microbiol. 2016 May;65(5):345-350. (PMID: 26872701)
Int J Mol Sci. 2019 Aug 12;20(16):. (PMID: 31408980)
Pathogens. 2023 Apr 14;12(4):. (PMID: 37111481)
Drug Deliv. 2022 Dec;29(1):1007-1024. (PMID: 35363104)
Front Microbiol. 2019 May 08;10:1033. (PMID: 31139166)
Front Immunol. 2021 Aug 10;12:702172. (PMID: 34447373)
Expert Opin Drug Deliv. 2014 Sep;11(9):1419-34. (PMID: 24960192)
Physiol Behav. 2020 Jun 1;220:112859. (PMID: 32156556)
Blood Cells Mol Dis. 2016 May;58:1-5. (PMID: 27067480)
Med Mycol. 2020 Apr 1;58(3):341-350. (PMID: 31254346)
Chem Rev. 2018 Feb 28;118(4):1691-1741. (PMID: 29319301)
Drug Deliv. 2016;23(2):550-63. (PMID: 24959937)
Am J Obstet Gynecol. 1989 Nov;161(5):1132-6. (PMID: 2686440)
J Microbiol Methods. 2000 Apr;40(2):175-9. (PMID: 10699673)
J Biomater Sci Polym Ed. 2018 Oct;29(15):1920-1934. (PMID: 30183550)
J Pharm (Cairo). 2018 May 16;2018:9285854. (PMID: 29862118)
Polymers (Basel). 2019 Jul 27;11(8):. (PMID: 31357570)
J Mycol Med. 2023 Mar;33(1):101329. (PMID: 36270212)
Iran J Basic Med Sci. 2016 Nov;19(11):1231-1237. (PMID: 27917280)
Drugs. 2019 Jun;79(8):833-853. (PMID: 31093949)
Food Chem. 2018 Dec 15;269:286-292. (PMID: 30100436)
PLoS Pathog. 2014 Apr 03;10(4):e1003965. (PMID: 24699903)
J Leukoc Biol. 2012 Jan;91(1):159-65. (PMID: 21965175)
Mini Rev Med Chem. 2009 Oct;9(11):1292-1305. (PMID: 19534688)
Mol Ther Nucleic Acids. 2021 Dec 16;27:517-523. (PMID: 35036062)
Ultrason Sonochem. 2018 Jan;40(Pt A):527-532. (PMID: 28946454)
Int J Mol Sci. 2022 Nov 13;23(22):. (PMID: 36430474)
Mycopathologia. 2019 Oct;184(5):615-623. (PMID: 31359292)
Front Microbiol. 2019 Jul 02;10:1466. (PMID: 31333606)
Front Immunol. 2018 May 24;9:1033. (PMID: 29881378)
Front Immunol. 2022 Dec 08;13:1031941. (PMID: 36569947)
Microbiol Spectr. 2023 Mar 27;:e0512422. (PMID: 36971589)
Foods. 2022 Nov 22;11(23):. (PMID: 36496563)
Adv Mater. 2010 Mar 12;22(10):1039-59. (PMID: 20401929)
J Colloid Interface Sci. 2009 Aug 15;336(2):756-60. (PMID: 19447401)
Pharmacogn Rev. 2017 Jul-Sep;11(22):104-122. (PMID: 28989245)
Int J Biol Macromol. 2021 Jan 1;166:621-632. (PMID: 33137389)
Int J Med Microbiol. 2020 Apr;310(3):151414. (PMID: 32173268)
Pharmaceutics. 2023 Sep 13;15(9):. (PMID: 37765278)
Front Microbiol. 2020 Jun 05;11:1117. (PMID: 32582081)
Materials (Basel). 2019 May 04;12(9):. (PMID: 31060208)
Phytomedicine. 2023 Jun;114:154800. (PMID: 37043980)
Med Mycol. 2022 May 5;60(5):. (PMID: 35482711)
Adv Drug Deliv Rev. 2023 Jul;198:114896. (PMID: 37211280)
Antibiotics (Basel). 2021 Jan 01;10(1):. (PMID: 33401404)
Food Chem. 2022 Apr 16;374:131629. (PMID: 34865929)
Annu Rev Biomed Eng. 2012;14:1-16. (PMID: 22524388)
فهرسة مساهمة: Keywords: Biofilm treatment; Candida albicans; Keratin microcapsules; Phytotherapeutic applications; Vaginal microflora; Vulvovaginal candidiasis
المشرفين على المادة: 0 (Oils, Volatile)
0 (Antifungal Agents)
تواريخ الأحداث: Date Created: 20240727 Date Completed: 20240808 Latest Revision: 20240811
رمز التحديث: 20240812
مُعرف محوري في PubMed: PMC11311128
DOI: 10.1021/acsami.4c07413
PMID: 39067028
قاعدة البيانات: MEDLINE
الوصف
تدمد:1944-8252
DOI:10.1021/acsami.4c07413